Publications - Hélène Losson - Page 1

The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptos...

Hélène Losson Gajulapalli, Sruthi Reddy Manon Lernoux Lee, Jin-Young Mazumder, Aloran Gérard, Déborah Seidel Carole Hahn, Hyunggu Christov, Christo Dicato, Mario ...

Published in Pharmacological Research

Despite the discovery of tyrosine kinase inhibitors (TKIs) for the treatment of breakpoint cluster region-Abelson (BCR-ABL) + cancer types, patients with chronic myeloid leukemia (CML) treated with TKIs develop resistance and severe adverse effects. Combination treatment, especially with a histone deacetylase (HDAC) 6 inhibitor (HDAC6i), appears to...

Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/M...

Manon Lernoux Michael Schnekenburger Hélène Losson Vermeulen, Koen Hahn, Hyunggu Gérard, Déborah Lee, Jin-Young Mazumder, Aloran Ahamed, Muneer Christov, Christo ...

Published in Clinical Epigenetics

Background: Chronic myeloid leukemia (CML) pathogenesis is mainly driven by the oncogenic breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) fusion protein. Since BCR-ABL displays abnormal constitutive tyrosine kinase activity, therapies using tyrosine kinase inhibitors (TKis) such as imatinib represent a major bre...

Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clin...

Hélène Losson Michael Schnekenburger Dicato, Mario Marc Diederich

Published in Molecules

The remarkable complexity of cancer involving multiple mechanisms of action and specific organs led researchers Hanahan and Weinberg to distinguish biological capabilities acquired by cancer cells during the multistep development of human tumors to simplify its understanding. These characteristic hallmarks include the abilities to sustain prolifera...